ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies that address resistance mechanisms in cancer. Founded in 2014 and headquartered in California, ORIC focuses on hormone-dependent cancers, precision oncology, and key tumor dependencies. The company does not currently generate revenue from product sales but is advancing a pipeline of therapies targeting therapeutic resistance in oncology.
- ORIC-114 - A brain-penetrant, orally bioavailable, irreversible inhibitor targeting EGFR exon 20, HER2 exon 20, and EGFR atypical mutations, developed for genetically defined cancers, including those with CNS metastases.
- ORIC-944 - An allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, developed for advanced prostate cancer, with plans for combination studies with androgen receptor inhibitors.
- ORIC-533 - An orally bioavailable small molecule inhibitor of CD73, targeting resistance mechanisms in chemotherapy and immunotherapy, developed for multiple myeloma.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Dominic Piscitelli Executive | Chief Financial Officer | Board member at Celyad Oncology SA (audit and compensation committees); Board member at Alterome Therapeutics, Inc. | Dominic Piscitelli has been CFO of ORIC since September 2019. Previously, he was CFO at AnaptysBio, Inc., and held finance roles at Medivation, Inc., Astellas Pharma US, and OSI Pharmaceuticals. He has extensive experience in financial management in the biotech sector. | |
Jacob M. Chacko, M.D. Executive | President and Chief Executive Officer | Chair of the board of directors at Bright Peak Therapeutics, Inc.; Board member at 4D Molecular Therapeutics, Inc. | Jacob M. Chacko, M.D., has been CEO of ORIC since May 2018 and President since May 2019. Previously, he was CFO at Ignyta, Inc., and held roles at TPG Capital and McKinsey & Company. He holds an M.D. from UCLA and an M.B.A. from Harvard Business School. | View Report → |
Mardi C. Dier Board | Director | CFO at Madrigal Pharmaceuticals, Inc.; Board member at Prelude Therapeutics, Inc. (audit committee), Synthekine, Inc., and Healthcare Royalty Partners | Mardi C. Dier has been a Director at ORIC since February 2020. She has held executive roles at Madrigal Pharmaceuticals, ACELYRIN, Inc., Ultragenyx Pharmaceutical, and Portola Pharmaceuticals. She has extensive experience in finance and biotech leadership. | |
Richard Heyman, Ph.D. Board | Chairman of the Board | Venture Partner at Arch Ventures; Board member at PMV Pharma, Vividion, Enliven Therapeutics, and RayzeBio, Inc.; Vice Chair of the Board of Trustees at the Salk Institute; Board member at the Foundation for AACR; Executive Committee Member at UCSD Moores Cancer Center | Richard Heyman, Ph.D., has been Chairman of ORIC's board since May 2018. He previously served as Acting CEO and President at ORIC. He is a seasoned biotech leader, having co-founded Aragon and Seragon Pharmaceuticals, both acquired by major pharmaceutical companies. | |
Steven L. Hoerter Board | Director | President and CEO of Deciphera Pharmaceuticals, Inc.; Board member at Deciphera Pharmaceuticals, Inc. | Steven L. Hoerter has been a Director at ORIC since August 2021. He is also the President and CEO of Deciphera Pharmaceuticals and has served on the boards of Constellation Pharmaceuticals and Ignyta, Inc. He has significant experience in oncology-focused biotech leadership. |
- Given the discontinuation of ORIC-101 due to insufficient efficacy, can you elaborate on the specific challenges and lessons learned that will be applied to your ongoing and future programs, particularly ORIC-944 in prostate cancer?
- With the initiation of the Phase 1 study for ORIC-114, how do you plan to demonstrate its CNS activity, and will you enroll patients with active brain metastases in the trial?
- Regarding your new PLK4 program, can you provide more details on the target product profile, including the selectivity for PLK4 and how breast cancer represents the optimal population for this approach?
- In light of the tumor heterogeneity and redundant resistance mechanisms observed in your ORIC-101 studies, how will you address these challenges in future trials to improve efficacy outcomes?
- Considering the lack of clinical benefit observed with ORIC-101 despite achieving target engagement, what steps are you taking to ensure that similar issues do not affect your other programs, such as ORIC-533, and how will you demonstrate its efficacy as a monotherapy before pursuing combination strategies?
No recent press releases or 8-K filings found for ORIC.